Walgreens, Express Scripts, Rite Aid Corporation, CVS Caremark and St. Jude Medical Inc. highlighted in Zacks Analyst Blog: PR Newswire CHICAGO, Jan. 15, 2013 CHICAGO, Jan. 15, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Walgreens (WAG), Express Scripts (ESRX), Rite Aid Corporation (RAD), CVS Caremark (CVS), and St. Jude Medical Inc. (STJ). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Today, Zacks is promoting Four daily picks are offered free. Here are highlights from Tuesday's Analyst Blog: Walgreens Discusses Growth Strategy Recently, Walgreens (WAG) debriefed the investors on its growth strategy for fiscal 2013, while discussing the current business environment and providing a recap of its performance in fiscal 2012. Fiscal 2012 Recap Despite a challenging year, Walgreens attained several milestones in fiscal 2012. The company made tuck-in acquisitions and forged a strategic partnership with Alliance Boots. Further, Walgreens launched its Balance Rewards loyalty program in September 2012, which has recorded more than 50 million registrations to date. The company generated record cash flow from operations of $4.4 billion in fiscal 2012 out of which $1.9 billion was returned back to its shareholders via stock repurchases and dividends. The payment of the largest quarterly dividend in the company's history was another takeaway in the fiscal. By adopting appropriate strategies, Walgreens was also able to convert its fiscal 2012 headwinds into tailwinds for the ongoing fiscal. Among these, the most important turnaround is the new multi-year pharmacy network agreement with pharmacy benefit manager Express Scripts (ESRX) (from September 2012), under which the company's pharmacy network has started filling prescriptions from Express Scripts customers. Growth Drivers for 2013 and Beyond The company's three-pronged strategy of providing a holistic Well Experience, improving the role of community pharmacy, and forging strategic alliances is likely to yield positive results. Notably, the company has left no stone unturned to bolster sales, ranging from a customer loyalty program to stimulate consumer demand to resorting to inorganic means. In order to supplement its Well Experience approach, Walgreens continues to enhance its products and services. Moreover, the company is currently investing in private brands such as Walgreens, Delish and Nice! among others. Furthermore, Walgreens is the largest provider of vaccinations and immunizations in the U.S., with respect to community pharmacy. As per management, about 70% Americans are without a primary care physician and over 30 million of the U.S. population will gain insurance coverage in 2014 under the health care reforms. Consequently, revenue contribution from this franchise is expected to be more significant. The strategic alliance with Alliance Boots has also allowed Walgreens to expand its worldwide foothold, especially in Europe. The company believes that the wholesale business of Alliance Boots should improve its supply-chain performance. Also worth mentioning in this context is Walgreens' increasing focus on emerging markets as the pharmaceutical sector in these markets present significant growth opportunities. Our Take The recent developments regarding Walgreens continues to display its strength in pursuing strategic initiatives as reflected in the bullish momentum of its stock price. The stock inched towards its 52-week high of $39.21 on January 11, 2013. Following its annual shareholders' meeting, estimate revision trends also reflect a bullish sentiment toward Walgreens over the last 7 days. The positive revisions in the Zacks Consensus Estimate for fiscal 2013 as well as fiscal 2014 underline these events. While fiscal 2012 was a challenging year for Walgreens, we look forward to fiscal 2013 with sublime optimism. We currently have a long-term Neutral recommendation on the stock which carries a Zacks Rank #3 (Hold). Its peers Rite Aid Corporation (RAD) carries a Zacks Rank #1 (Strong Buy) and CVS Caremark (CVS) carries a Zacks Rank #2 (Buy). St. Jude Reports Prelim 4Q Results Medical devices major, St. Jude Medical Inc. (STJ) released preliminary results for the 2012-fourth quarter. The company will report its financial results on Jan 23, before markets opens. St. Jude expects adjusted earnings for the quarter in the range of 90 cents—92 cents per share, surpassing its earlier guidance of 86 cents–88 cents. This compared with the Zacks Consensus Estimate of 89 cents for the quarter. Adjusted earnings exclude one-time item charges of 50 cents–60 cents per share related to restructuring and other corporate activities. Management stated that sales growth and cost reduction measures will lead to the improvement in earnings. Revenues Total revenues for the quarter, on a constant currency basis, are projected to be $1,372 million, down 1% year over year. The Zacks Consensus Estimate for revenues is $1,370 million. Segment Review Based on the above projections, revenues from the core Cardiac Rhythm Management (CRM) business declined 6% (5% on a constant currency basis) to $682 million. Within CRM, Implantable cardiac defibrillators (ICD) revenues were down 3% at $422 million. This segment continues to be plagued by the Durata lead issues. Pacemaker revenues declined 11% to roughly $260 million. Neuromodulation revenues decreased 7%, (down 6% in constant currency) year over year to $113 million. Revenues from St. Jude's Cardiovascular segment inched down 1% (up 1% in constant currency) to $338 million. Within Cardiovascular segment, structural heart devices revenues increased 1% to $152 million but the same from vascular offerings dipped 2% to $186 million. However, on a positive note, Atrial Fibrillation (AF) revenues climbed 10% (up 11% in constant currency) to $239 million in the quarter. About the company St. Jude, with a market cap of $11.80 billion, is a leading medical devices manufacturer maintaining a solid rate of growth over the past decade. We are impressed by the company's efforts in leveraging its margins by undertaking various restructuring initiatives and controlling expenses. Today, Zacks is promoting Four daily picks are offered free. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Media Contact Zacks Investment Research 800-767-3771 ext. 9339 email@example.com http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. SOURCE Zacks Investment Research, Inc. Website: http://www.zacks.com
Walgreens, Express Scripts, Rite Aid Corporation, CVS Caremark and St. Jude Medical Inc. highlighted in Zacks Analyst Blog:
Press spacebar to pause and continue. Press esc to stop.